摘要
目的 探究对呼吸道合胞病毒(RSV)毛细支气管炎患儿应用布地奈德结合重组人干扰素α1b雾化吸入的效果及对其肺功能指标的影响。方法 选取92例RSV毛细支气管炎患儿,采用Excel表格分组法分为实验组与参照组,每组46例。参照组给予基础方案治疗,实验组给予布地奈德结合重组人干扰素α1b雾化吸入治疗。比较两组治疗效果、症状与体征消失时间、肺功能指标[潮气量(TV)、呼气峰流速(PEF)、达峰时间比(TPTEF/TE)及达峰容积比(VPTEF/VE)]及炎性因子[白细胞介素-10(IL-10)及干扰素-γ(INF-γ)]水平。结果 实验组治疗总有效率97.83%高于参照组的86.96%,组间对比差异成立(P<0.05)。实验组症状与体征消失时间中肺部啰音、三凹征、喘息、咳嗽消失时间分别为(4.65±0.88)、(2.96±0.52)、(3.70±1.08)、(5.18±1.30)d,均短于参照组的(5.41±1.13)、(4.20±0.87)、(4.22±0.96)、(2.79±1.24)d,组间对比差异成立(P<0.05)。实验组肺功能指标中TV、PEF、TPTEF/TE及VPTEF/VE分别为(7.51±1.29)ml/kg、(5.73±1.54)L/s、(26.91±7.08)%、(29.84±5.33)%,均高于参照组的(6.35±1.47)ml/kg、(4.02±0.83)L/s、(23.25±6.46)%、(26.91±4.32)%,组间对比差异成立(P<0.05)。实验组炎性因子指标中IL-10及INF-γ水平分别为(28.06±5.37)、(38.25±6.43)ng/L,均高于参照组的(15.64±7.22)、(29.36±5.24)ng/L,组间对比差异成立(P<0.05)。结论 布地奈德结合重组人干扰素α1b雾化吸入治疗RSV毛细支气管炎患儿的效果较好,临床症状与体征消失时间短,肺功能指标及炎性因子水平改善明显,具有重要临床应用价值。
Objective To explore the effect of budesonide combined with recombinant human interferonα1b aerosol inhalation in children with respiratory syncytial virus (RSV) bronchiolitis and its influence on pulmonary function indexes.Methods 92 children with RSV bronchiolitis were selected and divided into an experimental group and a reference group using Excel table grouping method,with 46 cases in each group.The reference group was treated with basic regimen,and the experimental group was treated with budesonide and recombinant human interferon α1b aerosol inhalation.Both groups were compared in terms of therapeutic effect,disappearance time of symptom and sign,pulmonary function indexes[tidal volume (TV),peak expiratory flow rate (PEF),ratio of the time to reach peak tidal expiratory flow to total expiratory time (TPTEF/TE) and ratio of the volume to reach peak tidal expiratory flow to total expiratory volume (VPTEF/VE)]and inflammatory factors[interleukin-10 (IL-10) and interferon-γ (INF-γ)].Results The total effective rate of 97.83%in the experimental group was higher than that of 86.96%in the reference group,and the difference between groups was established (P<0.05).In the experimental group,the disappearance time of pulmonary rale,three-concave sign,wheezing and cough were (4.65±0.88),(2.96±0.52),(3.70±1.08) and (5.18±1.30) d,which were shorter than those of (5.41±1.13),(4.20±0.87),(4.22±0.96) and (2.79±1.24) d in the reference group,and the difference between groups was established (P<0.05).In the experimental group,the pulmonary function indexes of TV,PEF,TPTEF/TE and VPTEF/VE were (7.51±1.29) ml/kg,(5.73±1.54) L/s,(26.91±7.08)%and (29.84±5.33)%,respectively.They were higher than those of (6.35±1.47) ml/kg,(4.02±0.83) L/s,(23.25±6.46)%and(26.91±4.32)%in the reference group,and the difference between groups was established (P<0.05).The levels of IL-10 and INF-γ in the experimental group were (28.06±5.37) and (38.25±6.43) ng/L,respectively,which were higher than those of (15.64±7.22) and (29.36±5.24) ng/L in the control group,and the difference between groups was established (P<0.05).Conclusion Budesonide combined with recombinant human interferon α1b aerosol inhalation in the treatment of children with RSV bronchiolitis is effective,the disappearance time of clinical symptoms and signs is shortened,and the levels of pulmonary function indexes and inflammatory factors are significantly improved,which is of great clinical application value.
作者
马怀庆
杨春蕾
MA Huai-qing;YANG Chun-lei(Anqiu People's Hospital,Weifang 262100,China)
出处
《中国实用医药》
2024年第2期103-106,共4页
China Practical Medicine
